- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
UltraSight's AI-Powered Cardiac Ultrasound Guidance Gets FDA Nod
Indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) in adults, the AI Guidance software reportedly enables novice ultrasound users to obtain real-time cardiac imaging at the point of care.
The Food and Drug Administration (FDA) has granted 510(k) clearance for UltraSight’s AI Guidance software, which may provide improved access to cardiac monitoring by allowing novice ultrasound users to obtain and receive feedback on cardiac ultrasound imaging.
UltraSight said the adjunctive software employs an underlying artificial intelligence (AI) neural network to facilitate ultrasound probe positioning for optimal quality views of the heart. In a 2022 multicenter study, researchers examined the use of the technology by nine residents and registered nurses for 240 cardiac patients. They found that the AI Guidance software allowed successful assessment of left ventricular function 99.6 percent of the time, right ventricular size 93 percent of the time and the presence of significant pericardial effusion 100 percent of the time.
“Ultrasound is a predominant tool in patient diagnosis but its user-dependent functionality and subjectivity in image quality assessment have been hurdles in providing care for heart patients in multiple care settings,” noted Roberto Lang, M.D., the director of cardiovascular imaging at the University of Chicago. “UltraSight’s real-time AI guidance is a gamechanger for diagnostic efficiency and experience. Now with regulatory clearance, medical professionals and patients alike can benefit from this transformative cardiac imaging solution.”
Indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) in adults, the AI Guidance software is compatible with the Philips Lumify Ultrasound System, according to UltraSight.
(Editor’s note: For related content, see “Emerging AI Advances in Cardiac Imaging,” “Ultromics Gets HCPCS Code for AI-Powered EchoGo Heart Failure Device” and “AI Platform for Ultrasound Detection of Cardiac Amyloidosis Gets FDA Breakthrough Designation.”)
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
